Introduction: Recent data from the COMPARZ study seem to suggest a noninferiority of pazopanib confronted with sunitinib in PFS and OS. We previously reported how VEGF and VEGFR polymorphisms might have a predictive role in patients treated with first-line sunitinib. Aim of our study was to investigate whether tumour angiogenesis genotyping could influence clinical outcome in RCC patients treated with either sunitinib or pazopanib, in order to help clinicians select the appropriate treatment for each patient. Results: 19 patients were treated with pazopanib while 78 received sunitinib. VEGF A rs833061 resulted significant in PFS in sunitinib vs pazopanib patients (CC+CT > TT in sunitinib, TT > CC+CT in pazopanib; p < 0,0001); VEGF A rs2010963 resulted significant in PFS in sunitinib vs pazopanib patients (GG+CG > CC in sunitinib, CC > GG+CG in pazopanib; p < 0,0001); VEGF A rs699947 resulted significant in PFS in sunitinib vs pazopanib patients (AA+AC > CC in sunitinib, CC > AA+AC in pazopanib; p < 0,0001). OS showed no statistically significant difference. Conclusions: In our analysis patients with opposite polymorphisms of rs833061, rs2010963, rs699947 of VEGF A seems to have a better PFS if treated with either sunitinib or pazopanib. Our data seem to suggest that biology could have a role choosing first line treatment for mRCC patients. Methods: A retrospective analysis on 97 histologic samples of mRCC patients was conducted for VEGF-A, VEGF-C and VEGFR-1,2,3 single nucleotide polymorphisms (SNPs).
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma / M. Bianconi, L. Faloppi, C. Loretelli, A. Zizzi, R. Giampieri, A. Bittoni, K. Andrikou, M. Del Prete, L. Burattini, R. Montironi, M. Scartozzi, S. Cascinu. - In: ONCOTARGET. - ISSN 1949-2553. - 7:25(2016 May 09), pp. 37599-37607.
|Titolo:||Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma|
|Parole Chiave:||angiogenesis; Pazopanib; renal cell carcinoma; Sunitinib; VEGF; aged; aged, 80 and over; angiogenesis inhibitors; carcinoma, renal cell; female; genotype; humans; indoles; kidney neoplasms; male; middle aged; neovascularization, pathologic; polymorphism, single nucleotide; pyrimidines; pyrroles; receptors, vascular endothelial growth factor; retrospective studies; sulfonamides; vascular endothelial growth Factor A; oncology|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
Settore MED/03 - Genetica Medica
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
Settore MED/04 - Patologia Generale
Settore BIO/13 - Biologia Applicata
|Data di pubblicazione:||9-mag-2016|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.18632/oncotarget.9229|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.pdf||Publisher's version/PDF||Open Access Visualizza/Apri|